Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR FPBMC in Metastatic or Unresectable Pancreatic Cancer
NCT06479239Phase 2Recruiting
- Sponsor
- University of Virginia
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Cell Therapies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of EGFR FPBMC in pancreatic cancer (PC), sponsored by University of Virginia. Started Nov 2024; status: recruiting.
02
Drugs
EGFR FPBMC
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06479239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06479239.